Last reviewed · How we verify

ropivacaine plus mepivacaine

Centre Hospitalier Universitaire, Amiens · FDA-approved active Small molecule Quality 5/100

ropivacaine plus mepivacaine is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens. It is currently FDA-approved.

At a glance

Generic nameropivacaine plus mepivacaine
SponsorCentre Hospitalier Universitaire, Amiens
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ropivacaine plus mepivacaine

What is ropivacaine plus mepivacaine?

ropivacaine plus mepivacaine is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens.

Who makes ropivacaine plus mepivacaine?

ropivacaine plus mepivacaine is developed and marketed by Centre Hospitalier Universitaire, Amiens (see full Centre Hospitalier Universitaire, Amiens pipeline at /company/centre-hospitalier-universitaire-amiens).

What development phase is ropivacaine plus mepivacaine in?

ropivacaine plus mepivacaine is FDA-approved (marketed).

Related